生物標記合作與授權協議：2016-2025

Biomarker Collaboration and Licensing Deals 2016-2025

出版日期: 2025年11月01日 | 出版商:

Current Partnering | 英文 300+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告全面深入分析了全球領先的生物製藥公司簽署的生物標記協議，並提供前所未有的資訊取得管道。

本報告詳細闡述並分析了公司簽署生物標記協議的原因和方法。這些協議通常包含多個組成部分，從合作研發開始，最終實現成果的商業化。

本報告涵蓋合作研發、研究和授權協議。

本報告包含自2016年以來公佈的545項生物標誌物交易的完整清單，其中包括可用的財務條款以及指向各方披露的實際生物標誌物合作交易在線記錄的鏈接。此外，在條件允許的情況下，記錄中還包括公司及其合作夥伴向美國證券交易委員會提交的合約文件。

主要優勢：

了解自 2016 年以來的合約趨勢
查看生物標記領域的合作和授權協議
基準分析：確定交易市場價值
財務條款：預付款、里程碑付款、特許權使用費
依公司名稱（A-Z）、合約類型和治療領域分類的合約目錄
以價值排名的主要交易
最活躍的交易撮合者
識別每份合約的資產描述和條款
存取合約文件：深入了解合約結構
盡職調查：評估擬議合約條款是否適合您的合作夥伴
節省數百小時的研究時間

分析合約內容有助於進行以下方面的盡職調查：

合約授予或選擇哪些具體權利？
合約實際上賦予合作夥伴哪些權利？
授予了哪些獨家經營權？
合約的付款結構是怎樣的？
銷售和付款將如何審計？
合約期限是多久？
合約的關鍵條款是如何定義的？
智慧財產權（IPR）將如何處理，所有權歸誰？
誰負責商業化？
誰負責開發、供應和生產？
如何管理保密性和資訊揭露？
如何解決爭議？
在什麼情況下可以終止合約？
如果所有權發生變更，會發生什麼事？
雙方約定的轉授權和分包條款是什麼？
公司通常會包含哪些標準條款？
根據交易對手和合約類型，有哪些標準條款會有所不同？
根據合約法，公司要求適用哪個司法管轄區（法院）的法律？

This report contains a comprehensive listing of 545 biomarker deals announced since 2016 including financial terms where available including links to online deal records of actual biomarker partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of biomarker dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in biomarker dealmaking since 2016.

Chapter 3 provides an overview of the leading biomarker deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in biomarker dealmaking with a brief summary followed by a comprehensive listing of biomarker deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of biomarker deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since Jan 2016. The chapter is organized by specific biomarker technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in biomarker deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Biomarker Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2016
Browse biomarker collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, deal type and therapy area
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Biomarker Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of biomarker trends and structure of deals entered into by leading biopharma companies worldwide.

Biomarker Collaboration and Licensing Deals includes:

Trends in biomarker dealmaking in the biopharma industry
Directory of biomarker deal records covering pharmaceutical and biotechnology
The leading biomarker deals by value
Most active biomarker licensing dealmakers
Biomarker Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in biomarker dealmaking

2.1. Introduction
2.2. Biomarker deals over the years
2.3. Most active biomarker dealmakers
2.4. Biomarker deals by deal type
2.5. Biomarker deals by therapy area
2.6. Biomarker deals by industry sector
2.7. Deal terms for biomarker deals
- 2.7.1 Biomarker deals headline values
- 2.7.2 Biomarker deal upfront payments
- 2.7.3 Biomarker deal milestone payments
- 2.7.4 Biomarker royalty rates